YOU ARE HERE: LAT HomeCollectionsGlaxosmithkline Company

Glaxosmithkline Company

Two drug companies claimed in a federal lawsuit Wednesday that Idec Pharmaceuticals Corp.'s promising lymphoma treatment infringes their patents. Corixa Corp. and Britain-based GlaxoSmithKline said they are seeking a court order that would prevent Idec from selling Zevalin, an experimental drug that uses radioactivity to kill tumors. Corixa and GlaxoSmithKline are developing a rival cancer drug.
March 29, 2006 | From the Associated Press
The maker of the antidepressant Paxil has agreed to pay $14 million to states to settle allegations that it blocked generic versions of the drug from being made, forcing the states to pay higher prices. London-based GlaxoSmithKline denied any wrongdoing and was not admitting liability in making the settlement. "We made the decision that settling was appropriate to avoid the expense and distraction of protracted litigation," company spokeswoman Gaile Renegar said.
April 28, 2003 | From Bloomberg News
GlaxoSmithKline, Europe's largest drug maker, said Sunday that it is cutting prices on Combivir and its other AIDS treatments by as much as half for 63 of the world's poorest countries. Combivir, which is part of the World Health Organization's recommended standard treatment for HIV, will cost 90 cents a day for nonprofit groups, Glaxo said. Combivir had cost $1.70 a day since a price cut in September.
October 6, 2006 | From Newsday
The Food and Drug Administration on Thursday approved FluLaval, a new seasonal influenza vaccine from GlaxoSmithKline. The approval boosts the country's expected flu vaccine supply for this influenza season to about 115 million doses. It joins four other FDAapproved seasonal flu vaccines. FluLaval is for use in adults who are not allergic to eggs and chicken proteins. FluLaval has a wholesale price of about $10 a dose. It was licensed under the FDA's accelerated approval program.
August 11, 2006 | From Bloomberg News
GlaxoSmithKline said Thursday that it agreed to pay more than $70 million to settle claims by state attorneys general and consumers that the company overcharged government health programs for its medicines. The settlement covers claims by New York, California, Nevada, Connecticut, Montana and Arizona, as well as potential claims in 34 other states and the District of Columbia, the London-based company said.
British drug maker GlaxoSmithKline said Thursday that it settled litigation against Genentech Inc. that claimed its rival infringed patents covering monoclonal antibodies--cells grown in large fermentation tanks that can be programmed to attack disease. The companies did not disclose details of the confidential settlement, which ends two separate legal actions. As a result of the settlement, Glaxo dropped its appeal of a May 2001 jury verdict in favor of Genentech.
November 1, 2007 | From Times Wire Services
Pharmaceutical company GlaxoSmithKline won a preliminary injunction stopping the U.S. Patent and Trademark Office from implementing rules to streamline the patent application process, the patent office and Glaxo said. The rules would have gone into effect today. They would put limits on "claims," or how an applicant defines an invention, and on "continuations," the number of times an applicant can file for the same innovation.
February 9, 2003 | Catherine Saillant, Times Staff Writer
With a battle cry of "Tums down!" senior citizens groups have started a boycott of drug giant GlaxoSmithKline, after the company cut supplies to Canadian pharmacies that sell its drugs to Americans on the Internet at bargain prices. The seniors are taking aim at the British maker of Tums antacid, Aquafresh toothpaste, Contac cold remedy and dozens of common prescription medicines, calling Glaxo's decision "mean-spirited" and harmful to older people.
October 24, 2005 | Shari Roan, Times Staff Writer
Drugstore shelves are brimming with shakes, herbs and other products to facilitate weight loss -- but the vast majority of them have not been shown to work. It's possible that a proven medication that helps modestly with weight loss may join their ranks next year. The pharmaceutical company GlaxoSmithKline has asked the Food and Drug Administration for permission to sell a low-dose version of its diet drug Xenical over the counter.
March 14, 2007 | From Reuters
GlaxoSmithKline won U.S. approval Tuesday for a once-a-day breast cancer pill that the drug maker hopes will launch a new era for its oncology business. The Food and Drug Administration cleared the drug, called Tykerb, for patients with advanced breast cancer in combination with Roche Holding's oral chemotherapy drug, Xeloda, or capecitabine. It is the first of four cancer drugs that Glaxo hopes to have approved by 2010.
Los Angeles Times Articles